Subjects’ demographic and clinical characteristics by contralesional groups
| NAA/CrIncrease | NAA/CrNo Increase | |
|---|---|---|
| N | 14 | 13 |
| Age, baseline (years) | 63.3 ± 8.6 | 62.6 ± 10.1 |
| % Female | 43 | 69 |
| Time to follow-up (days) | 103.4 ± 16.6 | 116.7 ± 39.7 |
| Side of stroke (right/left) (N) | 6/8 | 6/7 |
| Lesion volume (mm3) | 28.3 ± 30.4* | 4.7 ± 8.0* |
| Lesion location | ||
| Subcortical (N) | 6 | 9 |
| Cortical (N) | 3 | 1 |
| Both (N) | 5 | 3 |
| Stroke risk factors | ||
| Hypertension (N) | 9 | 10 |
| Hypercholesterolemia (N) | 7 | 7 |
| Atrial fibrillation (N) | 1 | 2 |
| Diabetes (N) | 3 | 5 |
| NAA/Crcontralesional | ||
| Baseline | 1.50 ± .029* | 1.84 ± 0.38* |
| Follow-up | 1.87 ± 0.04* | 1.51 ± 0.26* |
| Change | 0.37 ± 0.32* | −0.32 ± 0.32* |
| NAA/Cripsilesional | ||
| Baseline | 1.66 ± 0.24 | 1.87 ± 0.44 |
| Follow-up | 1.50 ± 0.37 | 1.63 ± 0.17 |
| Change | −0.15 ± .47 | −0.23 ± .51 |
| SSS Scores | ||
| Baseline | 43.0 ± 10.2* | 50.3 ± 7.5* |
| Follow-up | 52.1 ± 5.3 | 54.1 ± 7.0 |
| Change | 9.1 ± 5.3* | 3.76 ± 3.1* |
| % Improvement | 25.4 ± 21.10* | 8.04 ± 6.8* |
Note:—NAA indicates N-acetylaspartate; Cr, creatine. Values are means ± SD.
*
P < 0.05